GW Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference

Rhea-AI Summary

GW Pharmaceuticals will present at the Stifel Virtual Healthcare Conference on November 18, 2020, at 1:20 pm EST. A live audio webcast will be accessible from their corporate website, with a replay available post-event. Renowned for its cannabinoid medicines, GW's lead product, EPIDIOLEX, is FDA-approved for treating seizures linked to Lennox-Gastaut syndrome and other conditions. The company is advancing multiple clinical programs, including treatments for multiple sclerosis and autism.

LONDON and CARLSBAD, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020 at 1:20 pm EST.

A live audio webcast of the presentation will be available through GW’s corporate website at www.gwpharm.com in the Investors section under Events & Presentations. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, EPIDIOLEX^® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX^® for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:

GW Pharmaceuticals plc
Scott Giacobello, Chief Financial Officer	760 795 2200

 

FAQ

What is the date of GW Pharmaceuticals' presentation at the Stifel Virtual Healthcare Conference?

GW Pharmaceuticals will present on November 18, 2020.

What time will GW Pharmaceuticals' presentation start at the Stifel Virtual Healthcare Conference?

The presentation will begin at 1:20 pm EST.

Where can I watch GW Pharmaceuticals' presentation at the Stifel Virtual Healthcare Conference?

You can watch the presentation live on GW's corporate website in the Investors section.

What is GW Pharmaceuticals' lead product for seizure treatment?

GW Pharmaceuticals' lead product for seizure treatment is EPIDIOLEX, which is approved for several conditions.

What conditions does EPIDIOLEX treat?

EPIDIOLEX is approved for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.

Is EPIDIOLEX approved in the European Union?

Yes, EPIDIOLEX is approved in the EU under the name EPIDYOLEX for certain seizure treatments.

What additional clinical programs is GW Pharmaceuticals developing?

GW Pharmaceuticals is advancing late-stage clinical programs for nabiximols for spasticity and other cannabinoid candidates for autism and schizophrenia.